Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

Presentation ACC 2025

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Presenter: Luke Laffin

March 29, 2025

Presentation Controversies and Advances 2025

Cuffless blood pressure devices: Are they ready for prime time?

Presenter: Jennifer L. Cluett

January 30, 2025

Presentation ESC 2024

BedMed and BedMed-Frail randomized controlled trials

Presenter: Scott Garrison

August 31, 2024

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

Presentation ACC 2024

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Presenter: Ronald Chi Hang Lee

April 06, 2024

Presentation Miami Valves 2024

Management of Pulmonary Hypertension: Cardiology Perspective

Presenter: Mrudula R. Munagala

February 01, 2024

Presentation Miami Valves 2024

Turning Point in Hypertension Care

Presenter: Maria Delgado-Lelievre

February 01, 2024

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

Presentation AHA 2023

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Presenter: Dike Ojji

November 17, 2023

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation

RDN to treat Resistant Hypertension

Presenter: Tai Kobayashi

November 10, 2023

Presentation EuroPCR 2023

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

Presenter: Yu-Jie Zhou

May 17, 2023

Presentation ACC 2023

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Presenter: Marius M. Hoeper

March 05, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation EuroPCR 2022

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Presenter: Ajay J. Kirtane, Michel Azizi

May 17, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Advertisement

Advance-HTN: Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension

Cuffless blood pressure devices: Are they ready for prime time?

BedMed and BedMed-Frail randomized controlled trials

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Primary Results from the Phase 2 KARDIA-2 Study

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Management of Pulmonary Hypertension: Cardiology Perspective

Turning Point in Hypertension Care

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

RDN to treat Resistant Hypertension

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

The STELLAR Phase 3 Trial: A Study of Sotaterceptin Combination with Background Therapy for the Treatment of Pulmonary Arterial Hypertension

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Current Status and Future of Renal Denervation for Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content